# Vera Therapeutics, Inc.: financial statements, quarterly

VERA · Nasdaq · CIK 1831828 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/vera.md) · [Financials](/companies/vera/financials.md) · [Filings](/companies/vera/filings.md) · [Insiders](/companies/vera/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/vera/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [16.1](/filings/0000950170-24-123239.md) | [20.8 d](/filings/0001193125-26-077442.md) | [23.2](/filings/0000950170-25-064733.md) | [29.3](/filings/0000950170-25-103022.md) | [40.3](/filings/0001193125-25-266881.md) | [33.3 d](/filings/0001193125-26-077442.md) | [41.3](/filings/0001193125-26-212143.md) | [58.2](/filings/0001193125-26-342380.md) | [56.5](/filings/0001193125-25-266881.md) | [59.3 d](/filings/0001193125-26-077442.md) | [86.0](/filings/0001193125-26-212143.md) | [60.1](/filings/0001193125-26-342380.md) |
| Operating income | $m | [(21.8)](/filings/0000950170-24-123239.md) | [(27.0) d](/filings/0001193125-26-077442.md) | [(31.1)](/filings/0000950170-25-064733.md) | [(37.3)](/filings/0000950170-25-103022.md) | [(49.8)](/filings/0001193125-25-266881.md) | [(48.9) d](/filings/0001193125-26-077442.md) | [(57.2)](/filings/0001193125-26-212143.md) | [(80.1)](/filings/0001193125-26-342380.md) | [(83.9)](/filings/0001193125-25-266881.md) | [(94.2) d](/filings/0001193125-26-077442.md) | [(125)](/filings/0001193125-26-212143.md) | [(112)](/filings/0001193125-26-342380.md) |
| Interest expense | $m | [0.9](/filings/0000950170-23-062139.md) | [1.1 d](/filings/0000950170-24-036729.md) | [1.9](/filings/0000950170-24-057292.md) | [1.9](/filings/0000950170-24-094108.md) | [1.9](/filings/0001193125-25-266881.md) | [1.9 d](/filings/0001193125-26-077442.md) | [1.8](/filings/0001193125-26-212143.md) | [1.9](/filings/0001193125-26-342380.md) | [2.0](/filings/0001193125-25-266881.md) | [1.9 d](/filings/0001193125-26-077442.md) | [1.8](/filings/0001193125-26-212143.md) | [1.8](/filings/0001193125-26-342380.md) |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(20.1)](/filings/0000950170-24-123239.md) | [(25.7) d](/filings/0001193125-26-077442.md) | [(28.4)](/filings/0001193125-25-266881.md) | [(33.7)](/filings/0001193125-25-266881.md) | [(46.6)](/filings/0001193125-25-266881.md) | [(43.4) d](/filings/0001193125-26-077442.md) | [(51.7)](/filings/0001193125-26-342380.md) | [(76.5)](/filings/0001193125-26-342380.md) | [(80.3)](/filings/0001193125-25-266881.md) | [(91.1) d](/filings/0001193125-26-077442.md) | [(121)](/filings/0001193125-26-342380.md) | [(109)](/filings/0001193125-26-342380.md) |
| Diluted EPS | $ per share | [(0.45)](/filings/0000950170-24-123239.md) | not reported | [(0.56)](/filings/0000950170-25-064733.md) | [(0.62)](/filings/0000950170-25-103022.md) | [(0.85)](/filings/0001193125-25-266881.md) | not reported | [(0.81)](/filings/0001193125-26-212143.md) | [(1.20)](/filings/0001193125-26-342380.md) | [(1.26)](/filings/0001193125-25-266881.md) | not reported | [(1.69)](/filings/0001193125-26-212143.md) | [(1.52)](/filings/0001193125-26-342380.md) |
| Basic EPS | $ per share | [(0.45)](/filings/0000950170-24-123239.md) | not reported | [(0.56)](/filings/0000950170-25-064733.md) | [(0.62)](/filings/0000950170-25-103022.md) | [(0.85)](/filings/0001193125-25-266881.md) | not reported | [(0.81)](/filings/0001193125-26-212143.md) | [(1.20)](/filings/0001193125-26-342380.md) | [(1.26)](/filings/0001193125-25-266881.md) | not reported | [(1.69)](/filings/0001193125-26-212143.md) | [(1.52)](/filings/0001193125-26-342380.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [27.4](/filings/0000950170-23-062139.md) | [45.7](/filings/0000950170-25-029969.md) | [69.1](/filings/0000950170-24-057292.md) | [25.1](/filings/0000950170-24-094108.md) | [27.3](/filings/0000950170-24-123239.md) | [92.6](/filings/0001193125-26-077442.md) | [55.1](/filings/0000950170-25-064733.md) | [49.1](/filings/0000950170-25-103022.md) | [57.8](/filings/0001193125-25-266881.md) | [355](/filings/0001193125-26-342380.md) | [114](/filings/0001193125-26-212143.md) | [48.9](/filings/0001193125-26-342380.md) |
| Current assets | $m | [172](/filings/0000950170-23-062139.md) | [172](/filings/0000950170-25-029969.md) | [416](/filings/0000950170-24-057292.md) | [395](/filings/0000950170-24-094108.md) | [364](/filings/0000950170-24-123239.md) | [651](/filings/0001193125-26-077442.md) | [606](/filings/0000950170-25-064733.md) | [571](/filings/0000950170-25-103022.md) | [511](/filings/0001193125-25-266881.md) | [729](/filings/0001193125-26-342380.md) | [616](/filings/0001193125-26-212143.md) | [527](/filings/0001193125-26-342380.md) |
| Total assets | $m | [176](/filings/0000950170-23-062139.md) | [176](/filings/0000950170-25-029969.md) | [419](/filings/0000950170-24-057292.md) | [397](/filings/0000950170-24-094108.md) | [369](/filings/0000950170-24-123239.md) | [656](/filings/0001193125-26-077442.md) | [610](/filings/0000950170-25-064733.md) | [579](/filings/0000950170-25-103022.md) | [518](/filings/0001193125-25-266881.md) | [735](/filings/0001193125-26-342380.md) | [622](/filings/0001193125-26-212143.md) | [533](/filings/0001193125-26-342380.md) |
| Current liabilities | $m | [24.6](/filings/0000950170-23-062139.md) | [22.3](/filings/0000950170-25-029969.md) | [14.5](/filings/0000950170-24-057292.md) | [18.4](/filings/0000950170-24-094108.md) | [26.5](/filings/0000950170-24-123239.md) | [25.4](/filings/0001193125-26-077442.md) | [21.9](/filings/0000950170-25-064733.md) | [33.6](/filings/0000950170-25-103022.md) | [41.9](/filings/0001193125-25-266881.md) | [53.5](/filings/0001193125-26-342380.md) | [45.1](/filings/0001193125-26-212143.md) | [48.3](/filings/0001193125-26-342380.md) |
| Total liabilities | $m | [51.9](/filings/0000950170-23-062139.md) | [73.9](/filings/0000950170-25-029969.md) | [65.8](/filings/0000950170-24-057292.md) | [69.4](/filings/0000950170-24-094108.md) | [79.5](/filings/0000950170-24-123239.md) | [78.5](/filings/0001193125-26-077442.md) | [75.2](/filings/0000950170-25-064733.md) | [110](/filings/0000950170-25-103022.md) | [119](/filings/0001193125-25-266881.md) | [130](/filings/0001193125-26-342380.md) | [122](/filings/0001193125-26-212143.md) | [125](/filings/0001193125-26-342380.md) |
| Long-term debt | $m | [25.0](/filings/0000950170-23-062139.md) | [49.9](/filings/0000950170-25-029969.md) | [50.1](/filings/0000950170-24-057292.md) | [50.3](/filings/0000950170-24-094108.md) | [50.5](/filings/0000950170-24-123239.md) | [50.7](/filings/0001193125-26-077442.md) | [50.9](/filings/0000950170-25-064733.md) | [74.5](/filings/0000950170-25-103022.md) | [74.6](/filings/0001193125-25-266881.md) | [74.8](/filings/0001193125-26-342380.md) | [75.0](/filings/0001193125-26-212143.md) | [75.2](/filings/0001193125-26-342380.md) |
| Shareholders' equity | $m | [124](/filings/0000950170-24-123239.md) | [102](/filings/0001193125-26-077442.md) | [354](/filings/0001193125-25-266881.md) | [328](/filings/0001193125-25-266881.md) | [289](/filings/0001193125-25-266881.md) | [577](/filings/0001193125-26-342380.md) | [535](/filings/0001193125-26-342380.md) | [468](/filings/0001193125-26-342380.md) | [399](/filings/0001193125-25-266881.md) | [605](/filings/0001193125-26-342380.md) | [500](/filings/0001193125-26-342380.md) | [408](/filings/0001193125-26-342380.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(23.0) d](/filings/0000950170-24-123239.md) | [(25.1) d](/filings/0001193125-26-077442.md) | [(33.8)](/filings/0000950170-25-064733.md) | [(24.8) d](/filings/0000950170-25-103022.md) | [(36.9) d](/filings/0001193125-25-266881.md) | [(39.2) d](/filings/0001193125-26-077442.md) | [(54.4)](/filings/0001193125-26-212143.md) | [(54.8) d](/filings/0001193125-26-342380.md) | [(61.9) d](/filings/0001193125-25-266881.md) | [(70.0) d](/filings/0001193125-26-077442.md) | [(107)](/filings/0001193125-26-212143.md) | [(100) d](/filings/0001193125-26-342380.md) |
| Capital expenditure | $m | [0.0 d](/filings/0000950170-24-123239.md) | [0.1 d](/filings/0001193125-26-077442.md) | [0.0](/filings/0000950170-25-064733.md) | [0.1 d](/filings/0000950170-25-103022.md) | [0.2 d](/filings/0001193125-25-266881.md) | [0.6 d](/filings/0001193125-26-077442.md) | [0.2](/filings/0001193125-26-212143.md) | [0.2 d](/filings/0001193125-26-342380.md) | [0.1 d](/filings/0001193125-25-266881.md) | [0.1 d](/filings/0001193125-26-077442.md) | [0.0](/filings/0001193125-26-212143.md) | [0.0 d](/filings/0001193125-26-342380.md) |
| Share repurchases | $m | not reported | [0.0 d](/filings/0001193125-26-077442.md) | not reported | not reported | not reported | [0.0 d](/filings/0001193125-26-077442.md) | not reported | not reported | not reported | [0.0 d](/filings/0001193125-26-077442.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [27.2](/filings/0000950170-23-062139.md) | [37.7](/filings/0000950170-24-057292.md) | [44.3](/filings/0000950170-24-094108.md) | [44.4](/filings/0000950170-24-123239.md) | [51.0](/filings/0000950170-25-064733.md) | [54.7](/filings/0000950170-25-103022.md) | [54.9](/filings/0001193125-25-266881.md) | [63.7](/filings/0001193125-26-212143.md) | [63.8](/filings/0001193125-26-342380.md) | [63.8](/filings/0001193125-25-266881.md) | [71.5](/filings/0001193125-26-212143.md) | [71.8](/filings/0001193125-26-342380.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 72,063,335 at 2026-07-29, from the cover of the [10-Q filed 2026-08-10](/filings/0001193125-26-342380.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.